Haleon (HLN) EPS (Basic) (2021 - 2025)

Haleon's (HLN) quarterly EPS (Basic) came in at $0.12 in Q4 2025, up 30.19% on a QoQ basis from $0.09 in Q4 2023.

Haleon (HLN) EPS (Basic) (2021 - 2025) Analysis & Trends

Haleon (HLN) has 4 years of EPS (Basic) data on file, last reported at $0.12 in Q4 2025.

Quarterly EPS (Basic) changed N/A year-over-year to $0.12 in Q4 2025, while the trailing twelve-month figure through Jun 2026 was $0.12 (changed N/A YoY) and the FY2025 annual result came in at $0.25, up 22.31% from the prior year.
EPS (Basic) advanced to $0.12 in Q4 2025, from $0.09 in the prior quarter.
In the past five years, EPS (Basic) ranged from a high of $113.67 in Q3 2022 to a low of $0.04 in Q2 2023.
A 4-year average of $16.32 and a median of $0.11 in 2022 frame the typical range for EPS (Basic).
Annual changes were most pronounced in 2022 — EPS (Basic) fell 12.99% — and 2023, when it retreated 15.65%.
Tracing HLN's EPS (Basic) over 4 years: stood at $0.13 in 2021, then declined by 12.99% to $0.11 in 2022, then slipped by 15.65% to $0.09 in 2023, then surged by 30.19% to $0.12 in 2025.
The last three EPS (Basic) figures came in at $0.12 (Q4 2025), $0.09 (Q4 2023), and $0.04 (Q2 2023), per Business Quant data.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EPS (Basic) (Qtr)
1	Haleon	43.71 Bn	42.75 Bn	-	-
2	Teva Pharmaceutical Industries	43.11 Bn	39.45 Bn	2.15 Bn	-0.49
3	Zoetis	31.62 Bn	29.94 Bn	1.05 Bn	2.07
4	Takeda Pharmaceutical	28.72 Bn	22.92 Bn	5.10 Bn	0.45
5	United Therapeutics	22.33 Bn	19.67 Bn	683.80 Mn	7.82
6	Viatris	18.83 Bn	17.95 Bn	1.46 Bn	-0.10
7	Neurocrine Biosciences	15.62 Bn	15.23 Bn	935.80 Mn	1.43
8	Elanco Animal Health	12.10 Bn	11.57 Bn	798.00 Mn	0.11
9	Dr Reddys Laboratories	10.11 Bn	9.94 Bn	-	-
10	Alkermes	8.25 Bn	7.60 Bn	397.90 Mn	0.00

Download Data